Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Sanara MedTech (SMTI) Gross Margin (2016 - 2025)

Historic Gross Margin for Sanara MedTech (SMTI) over the last 15 years, with Q3 2025 value amounting to 92.88%.

  • Sanara MedTech's Gross Margin rose 20700.0% to 92.88% in Q3 2025 from the same period last year, while for Sep 2025 it was 92.25%, marking a year-over-year increase of 20900.0%. This contributed to the annual value of 90.61% for FY2024, which is 26900.0% up from last year.
  • Per Sanara MedTech's latest filing, its Gross Margin stood at 92.88% for Q3 2025, which was up 20700.0% from 92.5% recorded in Q2 2025.
  • In the past 5 years, Sanara MedTech's Gross Margin ranged from a high of 92.88% in Q3 2025 and a low of 82.92% during Q3 2022
  • Over the past 5 years, Sanara MedTech's median Gross Margin value was 90.04% (recorded in 2024), while the average stood at 89.49%.
  • As far as peak fluctuations go, Sanara MedTech's Gross Margin skyrocketed by 413200bps in 2021, and later plummeted by -82000bps in 2022.
  • Over the past 5 years, Sanara MedTech's Gross Margin (Quarter) stood at 88.87% in 2021, then fell by -5bps to 84.53% in 2022, then increased by 6bps to 89.89% in 2023, then grew by 2bps to 91.45% in 2024, then increased by 2bps to 92.88% in 2025.
  • Its Gross Margin stands at 92.88% for Q3 2025, versus 92.5% for Q2 2025 and 92.17% for Q1 2025.